BusinessRitter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose IntoleranceBy Nasdaq OMXMay 3, 2018, 10:00 AM UTC